Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein.

Lenzo FL, Cance WG.

Transl Cancer Res. 2017 Aug;6(Suppl 6):S957-S960. doi: 10.21037/tcr.2017.06.05. No abstract available.

2.

Surgeon-Authored Virtual Laparoscopic Adrenalectomy Module Is Judged Effective and Preferred Over Traditional Teaching Tools.

Kurenov S, Cendan J, Dindar S, Attwood K, Hassett J, Nawotniak R, Cherr G, Cance WG, Peters J.

Surg Innov. 2017 Feb;24(1):72-81. doi: 10.1177/1553350616672971. Epub 2016 Oct 7.

3.

Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.

Marlowe TA, Lenzo FL, Figel SA, Grapes AT, Cance WG.

Mol Cancer Ther. 2016 Dec;15(12):3028-3039. Epub 2016 Sep 16.

4.

Synthesis and bioactivity of a Goralatide analog with antileukemic activity.

Li Z, Lebedyeva IO, Golubovskaya VM, Cance WG, Alamry KA, Faidallah HM, Dennis Hall C, Katritzky AR.

Bioorg Med Chem. 2015 Aug 1;23(15):5056-60. doi: 10.1016/j.bmc.2015.04.061. Epub 2015 May 14.

PMID:
26048023
5.

Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.

Golubovskaya V, O'Brien S, Ho B, Heffler M, Conroy J, Hu Q, Wang D, Liu S, Cance WG.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1613-31. doi: 10.1007/s00432-015-1924-3. Epub 2015 Feb 6.

PMID:
25656374
6.

A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN, Cance WG.

Cell Cycle. 2014;13(16):2542-53. doi: 10.4161/15384101.2015.941760.

7.

High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.

Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, Cance WG.

BMC Cancer. 2014 Oct 17;14:769. doi: 10.1186/1471-2407-14-769.

8.
9.

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.

Dy GK, Ylagan L, Pokharel S, Miller A, Brese E, Bshara W, Morrison C, Cance WG, Golubovskaya VM.

J Thorac Oncol. 2014 Sep;9(9):1278-84. doi: 10.1097/JTO.0000000000000248.

10.

The use of modified four-dimensional computed tomography in patients with primary hyperparathyroidism: an argument for the abandonment of routine sestamibi single-positron emission computed tomography (SPECT).

Kukar M, Platz TA, Schaffner TJ, Elmarzouky R, Groman A, Kumar S, Abdelhalim A, Cance WG.

Ann Surg Oncol. 2015 Jan;22(1):139-45. doi: 10.1245/s10434-014-3940-y. Epub 2014 Jul 30.

PMID:
25074663
11.

Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.

Gogate PN, Kurenova EV, Ethirajan M, Liao J, Yemma M, Sen A, Pandey RK, Cance WG.

Cancer Lett. 2014 Oct 28;353(2):281-9. doi: 10.1016/j.canlet.2014.07.032. Epub 2014 Jul 24.

12.

In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride).

Golubovskaya V, Curtin L, Groman A, Sexton S, Cance WG.

Arch Toxicol. 2015 Jul;89(7):1095-101. doi: 10.1007/s00204-014-1290-y. Epub 2014 Jun 12.

PMID:
24915938
13.

Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.

Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG.

Eur J Med Chem. 2014 Jun 10;80:154-166. doi: 10.1016/j.ejmech.2014.04.041. Epub 2014 Apr 15.

14.

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.

Golubovskaya VM, Ho B, Conroy J, Liu S, Wang D, Cance WG.

Cancers (Basel). 2014 Jan 21;6(1):166-78. doi: 10.3390/cancers6010166.

15.

The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.

Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG.

Oncotarget. 2013 Oct;4(10):1632-46.

16.

Translational cancer research for surgeons.

Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):xv-xvi. doi: 10.1016/j.soc.2013.06.013. Epub 2013 Jul 3. No abstract available.

PMID:
24012406
17.

Targeting the p53 pathway.

Golubovskaya VM, Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30. Review.

18.

Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Stewart JE, Ma X, Megison M, Nabers H, Cance WG, Kurenova EV, Beierle EA.

Mol Carcinog. 2015 Jan;54(1):9-23. doi: 10.1002/mc.22070. Epub 2013 Jul 19.

19.

Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.

Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, Cance WG.

BMC Cancer. 2013 Jul 11;13:342. doi: 10.1186/1471-2407-13-342.

20.

Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.

Cance WG, Kurenova E, Marlowe T, Golubovskaya V.

Sci Signal. 2013 Mar 26;6(268):pe10. doi: 10.1126/scisignal.2004021. Review.

Supplemental Content

Loading ...
Support Center